La cadena de opciones muestra datos clave de las opciones de acciones de Eledon Pharma a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Eledon Pharma..

Eledon Pharma (NASDAQ:ELDN) Bolsa, Cadena de Opciones

Eledon Pharma

Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharmaceuticals Inc

HC Wainwright &amp; Co. analyst Heiko Ihle maintains Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) with a Buy and raises the price target from $7 to $7.25.

News

Price Target

Analyst Ratings

HC Wainwright & Co. Maintains Buy on Endeavour Silver, Raises Price Target to $7.25

For Q1 2025:
<ul>
<li>Consolidated revenue from continuing operations (which includes Power discrete and Power IC businesses, and excludes our former Display business) to be in the range of $42 to $47 million, down 8.9% sequentially due primarily to seasonality, but up 11.5% year-over-year at the mid-point. This compares with equivalent revenue of $48.9 million in Q4 2024 and $39.9 million in Q1 2024.</li>
<li>Consolidated gross profit margin from continuing operations to be in the range of 18.5% to 20.5%, due to the seasonal sequential decline in revenue and the wind down of Transitional Foundry Services impacting fab utilization. This compares with equivalent gross profit margin of 23.2% in Q4 2024 and 17.6% in Q1 2024.</li>
</ul>

Guidance

Magnachip Expects Q1 Revenue From Continuing Operations Of $42M-$47M, Up 11.5% YoY

Financing

VSTE

Vast Renewables Limited Receives Up To AUD180M Of Conditional Funding From Australian Renewable Energy Agency For Construction Of Its Port Augusta Utility-Scale Clean Energy Project

Full-Year 2025 Guidance
In 2025, the Company expects to generate Adjusted EBITDA between $1.6 billion and $2.2 billion and Adjusted EBIT between $350 million and $950 million.

Earnings

ZIM Integrated Shipping Services 2025 Outlook: Expects Adjusted EBITDA Of $1.6B-$2.2B And Adjusted EBIT Of $350M-$950M

AMRN

Amarin Intends To Effect Ratio Change On ADSs From One ADS Representing One Ordinary Share To New Ratio Of One ADS Representing 20 Ordinary Shares

HC Wainwright &amp; Co. analyst Scott Buck reiterates Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) with a Buy and maintains $26 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Redwire, Maintains $26 Price Target

Stock Split

Amarin To Effect An ADS Ratio Change From One ADS Representing One Ordinary Share To One ADS Representing Twenty Ordinary Shares

Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) reported quarterly earnings of $0.03 per share which missed the analyst consensus estimate of $0.11 by 72.73 percent. This is a 76.92 percent decrease over earnings of $0.13 per share from the same period last year. The company reported quarterly sales of $143.537 million which missed the analyst consensus estimate of $162.060 million by 11.43 percent. This is a 13.18 percent decrease over sales of $165.318 million the same period last year.

Earnings Misses

Solo Brands Q4 2024 Adj. EPS $0.03 Misses $0.11 Estimate, Sales $143.537M Miss $162.060M Estimate

InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.20) by 5 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $1.95 million which beat the analyst consensus estimate of $1.82 million by 7.29 percent. This is a 10.68 percent increase over sales of $1.76 million the same period last year.

NSPR

InspireMD Q4 2024 GAAP EPS $(0.19) Beats $(0.20) Estimate, Sales $1.95M Beat $1.82M Estimate

Earnings Beats

HBIO

Harvard Bioscience Q4 2024 Adj. EPS $0.06 Beats $0.05 Estimate, Sales $24.556M Beat $24.150M Estimate

HC Wainwright &amp; Co. analyst Amit Dayal reiterates Eve Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVEX#NYSE">EVEX</a>) with a Buy and maintains $6 price target.

EVEX

HC Wainwright & Co. Reiterates Buy on Eve Holding, Maintains $6 Price Target

Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.05) by 60 percent. The company reported quarterly sales of $62.31 million which beat the analyst consensus estimate of $35.92 million by 73.48 percent. This is a 16.61 percent decrease over sales of $74.71 million the same period last year.

Amarin Corp Q4 2024 Adj EPS $(0.02) Beats $(0.05) Estimate, Sales $62.31M Beat $35.92M Estimate

Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) reported quarterly earnings of $0.46 per share which beat the analyst consensus estimate of $0.45 by 2.22 percent. This is a 13.21 percent decrease over earnings of $0.53 per share from the same period last year. The company reported quarterly sales of $14.07 million which missed the analyst consensus estimate of $15.81 million by 11.02 percent. This is a 5.20 percent decrease over sales of $14.84 million the same period last year.

REFI

Chicago Atlantic Real Q4 Adj $0.46 Beats $0.45 Estimate, Sales $14.07M Miss $15.81M Estimate

Biotech

General

RDHL

RedHill Biopharma Initiates Phase 2 Study Of RHB-204 In Mycobacterium Avium Subspecies Paratuberculosis-Positive Moderate To Severe CD

Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.51 by 9.8 percent. The company reported quarterly sales of $287.49 million which beat the analyst consensus estimate of $265.88 million by 8.12 percent.

SDHC

Smith Douglas Homes Q4 2024 GAAP EPS $0.46 Misses $0.51 Estimate, Sales $287.49M Beat $265.88M Estimate

ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.78 by 11.54 percent. This is a 1.16 percent increase over earnings of $0.86 per share from the same period last year. The company reported quarterly sales of $2.11 billion which beat the analyst consensus estimate of $2.09 billion by 1.07 percent. This is a 2.17 percent increase over sales of $2.07 billion the same period last year.

ABM Indus Q1 2025 Adj EPS $0.87 Beats $0.78 Estimate, Sales $2.11B Beat $2.09B Estimate

iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) reported quarterly losses of $(2.06) per share which missed the analyst consensus estimate of $(1.73) by 19.08 percent. This is a 13.19 percent decrease over losses of $(1.82) per share from the same period last year. The company reported quarterly sales of $172.03 million which beat the analyst consensus estimate of $171.00 million by 0.60 percent. This is a 44.06 percent decrease over sales of $307.54 million the same period last year.

IRBT

iRobot Q4 Adj $(2.06) Misses $(1.73) Estimate, Sales $172.03M Beat $171.00M Estimate

ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) reported quarterly earnings of $4.66 per share which beat the analyst consensus estimate of $3.49 by 33.52 percent. This is a 478.86 percent increase over losses of $(1.23) per share from the same period last year. The company reported quarterly sales of $2.17 billion which beat the analyst consensus estimate of $2.06 billion by 5.33 percent. This is a 79.92 percent increase over sales of $1.21 billion the same period last year.

ZIM Integrated Shipping Q4 2024 GAAP EPS $4.66 Beats $3.49 Estimate, Sales $2.17B Beat $2.06B Estimate

Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) reported quarterly sales of $175.91 million which beat the analyst consensus estimate of $172.13 million by 2.19 percent. This is a 6.55 percent decrease over sales of $188.24 million the same period last year.

CRLBF

Cresco Labs Q4 Sales $175.91M Beat $172.13M Estimate, Net income of $0.4M

Geoblocking policies in cryptocurrency airdrops may have cost Americans up to $2.6 billion in potential earnings from 2020 to 2024, a report released Monday revealed.
What Happened:&nbsp;Dragonfly, a cryptocurrency-focused venture capital firm, published a <a href="https://airdropreport2025.dragonfly.xyz/Dragonfly-s-State-of-Airdrops-Report-2025-1b1af13b644180c8aff9c2bd0d222e14">report </a>detailing the financial impact of geoblocking policies on U.S. users in <a href="https://www.benzinga.com/money/what-is-a-crypto-airdrop">airdrops</a>—a marketing stunt that involves sending free tokens to users to promote a project and drive engagement.
According to the report, 11 out of the 12 airdrops analyzed used geoblockers to prevent&nbsp;U.S. residents from participating or&nbsp;receiving tokens. Due to these geographical restrictions, U.S. users may have missed out on anywhere&nbsp;between $1.84 and $2.64 billion&nbsp;in potential revenue from 2020-2024.
Moreover, the Treasury Department may have missed federal tax revenue of up to $1.38 billion due to geoblocked airdrop income. 
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/25/03/44267582/us-house-committee-favors-stablecoin-regulation-to-strenthen-dollar-advocates-against-cbdc">House Committee Favors Stablecoin Regulation To &#8216;Strengthen&#8217; Dollar: Majority Whip Says CBDCs Against &#8216;American Values&#8217;</a>
The report included analysis&nbsp;of token airdrops&nbsp;such as ApeCoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">APE</a>), linked to the Bored Ape Yacht Club non-fungible token, in addition to&nbsp;Arbitrum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ARB</a>) and EigenLayer (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">EIGEN</a>).
Why It Matters: The SEC&#8217;s position on cryptocurrency airdrops has been ambiguous, with non-binding guidance in 2019 indicating that an airdrop &#8220;may constitute&#8221; a sale or distribution of securities. 
The agency hasn&#8217;t issued a comprehensive regulation, though, specifically addressing airdrops. To be on the safer side, many cryptocurrency projects started blocking U.S. residents from accessing airdrops.
A few <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/40920107/gary-gensler-led-sec-should-clarify-crypto-airdrop-rules-gop-representatives-demand">prominent members</a> of Congress wrote to former SEC Chair Gary Gensler in September 2024, pressing for clarity on the regulatory stance. 
Over the years, scammers have <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36740248/hackers-steal-580-000-with-fake-airdrop-links-in-phishing-mail-scam">exploited the allure of airdrops</a> or free tokens to con unsuspecting users. The modus operandi involves creating fake airdrop campaigns, which impersonate legitimate projects, and then using deceptive tactics to trick users into connecting their wallets to phishing websites.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/25/03/44268317/sec-postpones-approval-of-several-crypto-spot-etfs-says-influential-analyst">Dogecoin, XRP ETF Filings Delayed By SEC But Influential Analyst Says &#8216;Relatively High&#8217; Odds Of Approval</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$APE

$ARB

$EIGEN

US Crypto Users Missed Receiving Over $2.5 Billion In Airdrops Due To Geoblocking: Report

Press Releases

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Eledon Pharmaceuticals to Participate in Guggenheim Securities SMID Cap Biotech Conference

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

ELDN

Abeona Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Eledon Pharma

Eledon Pharma (ELDN) Opciones

Eledon Pharma (NASDAQ:ELDN) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL